Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMQ8J0U)

Drug Name	Basmisanil DMQ8J0U
Synonyms	1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Immune dysregulation	DISZV2UF	4A01.2	Phase 2	[1]
Cognitive impairment	DISH2ERD	6D71	Phase 2	[2]
Alzheimer disease	DISF8S70	8A20	Phase 2	[3]
Complete androgen insensitivity syndrome	DISQL418	LD2A.4	Phase 2	[1]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3	ClinicalTrials.gov (NCT02484703) A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age.